Related Experiment Video
Updated: Jun 28, 2026
14:18
Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis
Gaosi Xu1, Weiping Tu, Dongfeng Jiang
1Department of Nephrology, Second Affiliated Hospital, Nanchang University, 1 Minde Road, Nanchang, PR China. xugaosi@gmail.com
American Journal of Nephrology
|November 1, 2008
Summary
Mycophenolate mofetil (MMF) does not significantly improve kidney function or reduce proteinuria in IgA nephropathy (IgAN) patients. Current evidence does not support its routine use in IgAN treatment.
Area of Science:
- Nephrology
- Immunosuppression
- Glomerular Diseases
Background:
- IgA nephropathy (IgAN) is the most prevalent form of glomerulonephritis globally.
- Mycophenolate mofetil (MMF) is an immunosuppressant with selective action on lymphocytes and B cells.
- Previous randomized controlled trials (RCTs) have explored MMF's efficacy in IgAN.
Purpose of the Study:
- To conduct a meta-analysis of all available RCTs on MMF treatment for IgAN.
- To evaluate the benefits and risks of MMF compared to placebo or steroids in IgAN patients.
Main Methods:
- Comprehensive searches of PubMed and Cochrane Library databases were performed.
- References from identified studies were reviewed for additional relevant trials.
- RCTs comparing MMF with placebo or steroids for IgAN treatment were included.
Main Results:
- Four RCTs with a total of 168 patients met the inclusion criteria.
- MMF treatment did not demonstrate statistically significant reductions in proteinuria.
- MMF did not show significant benefits in protecting renal function for IgAN patients.
Conclusions:
- Existing evidence does not support the routine administration of MMF for IgAN.
- Larger, international collaborative studies are recommended to further investigate MMF's role in IgAN.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...